What Was Announced on October 29
At the National Policy Coordination Meeting on October 29, the Ministry of Health and Welfare and the Ministry of SMEs and Startups jointly announced the "K-Pharma-Bio Frontier Company" development plan. The two ministries will jointly select 50 companies a year, for a total of 200 by 2030. At a September 17 industry meeting the plan was described as "in preparation." It is now final.
The government's targets for 2030 are 500 new pharma-bio SME startups and $5.5 billion in exports. The earlier "Pharma-Bio Venture Full-Cycle Collaboration Plan" (4UP / growth ladder) focused on linking each ministry's programs from one stage to the next. The new plan is different: it combines the policy tools of both ministries into a single selection and support track.
Three Fields and How Many Companies Each
Reported annual selection numbers:
The bio-materials and manufacturing field is open to CDMOs and companies that supply bio materials, parts and equipment. Three questions can help you decide which field to apply in:
Support Structure: Two Years, Then Three More
Reports disagree on the funding figures. Some describe "KRW 60 billion in investment plus KRW 90 billion in commercialization guarantees over three years." Others give only a total of KRW 150 billion. Check the government's official briefing and the detailed call for applications for exact numbers.
The government has said follow-on evaluations will not be based only on revenue or licensing deals. This means companies with long development timelines can still get credit for interim progress. So design clear milestones from the start, such as completing preclinical work, filing an IND or obtaining a certification. These milestones will largely decide whether you reach Phase 2.
Joint Steering Committee and Designation Revocation
A joint steering committee run by both ministries will decide the support fields, the evaluation criteria, which companies are selected, and when a designation is revoked. Because revocation is written into the plan, selected companies will need a system for tracking and reporting their performance.
The detailed call for applications has not yet been published. It will cover eligibility, the application schedule and how the growth directors will work. Keep watching the websites of both ministries, K-Startup and the Korea Health Industry Development Institute (KHIDI).
New R&D Running Alongside: Animal-Alternative Testing and AI Healthcare
Companies can compete for these new projects separately from Frontier selection. They are worth a look for organoid and organ-on-chip platform companies, preclinical CROs and medical AI software developers.
What to Prepare Before the Call Opens
How KITIM Can Help
KITIM helps pharma-bio companies prepare for Frontier selection. We advise on choosing a field, writing the growth strategy and designing five-year milestones. We also build funding portfolios that link government R&D with clinical support programs. If you want to start preparing before the detailed call is released, please contact KITIM through our inquiry page to book a consultation.
